Karonen, Tiina <br/><br/>
CYP2C8 but not CYP3A4 is important in the pharmacokinetics of montelukast.  [electronic resource] 

 -  British journal of clinical pharmacology  Feb 2012 
 - 257-67 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase IV; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1365-2125 
<br/><br/><label>Standard No.: </label>10.1111/j.1365-2125.2011.04086.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>14-alpha Demethylase Inhibitors--pharmacology<br/>Acetates--pharmacokinetics<br/>Adult<br/>Anti-Asthmatic Agents--pharmacokinetics<br/>Area Under Curve<br/>Aryl Hydrocarbon Hydroxylases--physiology<br/>Cross-Over Studies<br/>Cyclopropanes<br/>Cytochrome P-450 CYP2C8<br/>Cytochrome P-450 CYP3A--physiology<br/>Drug Interactions<br/>Female<br/>Gemfibrozil--pharmacology<br/>Humans<br/>Hypolipidemic Agents--pharmacology<br/>Itraconazole--pharmacology<br/>Male<br/>Quinolines--pharmacokinetics<br/>Sulfides<br/>Young Adult